Virios Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIRI research report →
Companywww.virios.com
Virios Therapeutics, Inc. , a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
- CEO
- Gregory Duncan
- IPO
- 2020
- Employees
- 4
- HQ
- Alpharetta, GA, US
Price Chart
Valuation
- Market Cap
- $206.50K
- P/E
- 0.00
- P/S
- 0.00
- P/B
- 0.06
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 339.80%
- ROIC
- -25394.77%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-35,514,032 · 99.72%
- EPS
- $-7.13 · 43.05%
- Op Income
- $-27,968,445,000
- FCF YoY
- -77.67%
Performance & Tape
- 52W High
- $26.00
- 52W Low
- $0.14
- 50D MA
- $4.51
- 200D MA
- $7.69
- Beta
- 1.58
- Avg Volume
- 87.79K
Get TickerSpark's AI analysis on VIRI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 26, 24 | Pridgen William | other | 2,917 |
| Feb 26, 24 | Thomas John C | other | 4,167 |
| Feb 26, 24 | Whitley Richard James | other | 4,000 |
| Feb 26, 24 | Keefer David R | other | 4,709 |
| Feb 26, 24 | Burch Richard Alan | other | 2,917 |
| Feb 26, 24 | De La Rosa Abel | other | 3,959 |
| Feb 26, 24 | Walsh Angela | other | 63,618 |
| Feb 26, 24 | Grosswald Ralph | other | 62,568 |
| Feb 26, 24 | Gendreau Roger Michael | other | 88,085 |
| Feb 26, 24 | Duncan Gregory Scott | other | 138,835 |
Our VIRI Coverage
We haven't published any research on VIRI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VIRI Report →